| Trial ID: | L1145 |
| Source ID: | NCT02049346
|
| Associated Drug: |
Epoetin Alpha Or Beta (Epoetin Group)
|
| Title: |
Comparison Among Erythropoietin Stimulating Agents
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Anemia of End Stage Renal Disease
|
| Interventions: |
DRUG: Epoetin alpha or beta (Epoetin group)|DRUG: Darbepoetin alfa|DRUG: Methoxy polyethylene glycol-epoetin beta
|
| Outcome Measures: |
Primary: Comparison of efficacy among erythropoetin stimulating agents., To evaluate efficacy of continuous erythropoietin receptor activator (C.E.R.A.) and Darbepoetin Alfa, to maintain Hemoglobin level - within the target recommended range - among ESRD patients, in direct comparison to currently available ESA (Epoetin alfa and beta). by measuring percentage of cases with mean Hemoglobin concentration between 11-12 gm/dl and measuring mean monthly hemoglobin concentrations., Every week up to 36 weeks | Secondary: comparison between safety profile of different types of erythropoetin simulating agents., To compare the safety profile of the three groups (Epoetin, Darbepoetin alpha, C.E.R.A.) by the prevalence of associated morbidity and mortality., Up 36 weeks
|
| Sponsor/Collaborators: |
Sponsor: Hamad Medical Corporation
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
327
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-03
|
| Completion Date: |
2013-06
|
| Results First Posted: |
|
| Last Update Posted: |
2017-09-13
|
| Locations: |
Fahd Bin Jassem Dialysis Centre, Doha, 30550, Qatar
|
| URL: |
https://clinicaltrials.gov/show/NCT02049346
|
